Research

September 2019

A Systematic Review and Meta-analysis

According to a GoodRx analysis, the price for all drugs, brand and generic, has increased by 32% since 2014.

In recent months, the pace of drug price hikes has cooled down.

Orphan drugs are one of the biggest factors driving out of control drug prices in the United States.

The administration has argued for a focus on Part B drugs because of the limited role that competitive forces play in determining what Medicare pays for these drugs.

Academic studies consistently show that a reduction in current drug revenues leads to a fall in future research and the number of new drug discoveries.

Annual Public Drug Plan Expenditure Report, 2017/18

Applications to Kidney Diseases

Neeraj Sood explains the three common alternatives to typical market-rate drug pricing: pure subscription, modified subscription, and volume-based discount.

Wendell Primus talks about how, under a clear mandate and instructions, the HHS Secretary could oversee a drug pricing model that rewards companies for innovation, but also lowers prices for patients.

Universal health coverage depends on affordable medicines. But pushing down prices without also investing in quality assurance will increase the sale of substandard and falsified drugs.

How healthcare data can help emerging economies.

VoxCheck explains healthcare in different countries. Which one is the most suitable and comfortable for the citizens, is up to readers